Tivic Health Systems, Inc. (NASDAQ:TIVC) shares are climbing Thursday on heavy trading volume. The company recently announced three new patents in the U.S. and Europe.
What To Know:
Tivic Health's stock is one of the top trending tickers on Yahoo Finance as retail investors pile into the health technology company's stock. According to Benzinga Pro, more than 65 million shares have been traded in Thursday's session, compared to the stock's float of just over 6 million shares.
Tivic Health announced on Tuesday it has received patent grants from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) both titled "Adaptive Trigger For a Microcurrent Stimulation Device" and a patent entitled "Sinus Treatment Device With Adaptive Circuit" from the EPO.
The company is focused on developing and commercializing non-invasive bioelectronic medicine. ClearUP Sinus Relief is Tivic Health's patented handheld device that uses ultra-low current electrical waves to relieve sinus pain and congestion symptoms that are prevalent in nasal allergies, sinus infections, chronic sinusitis, cold and flu and other disease conditions.
According to data from Benzinga Pro, Tivic Health shares are trading below the stock's 50-day moving average of 40 cents and near its 52-week low of 28 cents.
How To Buy TIVC Stock:
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in Tivic Health Systems' case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
TIVC Price Action: According to Benzinga Pro, Tivic Health shares finished 34.8% higher at 41 cents on Thursday.
Read Also:
- Viking Therapeutics Stock Climbs On Q2 EPS Beat $VKTX
Image: PublicDomainPictures from Pixabay